Group 1 - The Low Volatility Dividend Index (H30269.CSI) includes 50 securities with good liquidity, continuous dividends, moderate payout ratios, positive growth in dividends per share, high dividend yields, and low volatility, with a dividend yield of 4.13% as of November 28 [1] - The Dividend Quality Index (931468.CSI) consists of 50 securities that provide continuous cash dividends, have higher payout ratios, and exhibit high profitability, with a dividend yield of 3.45% as of November 28 [1] - The Low Volatility Dividend ETF (159547) is the ETF with the lowest comprehensive fee tracking the Low Volatility Dividend Index [1] - The Dividend Quality ETF (159758) is the only ETF tracking the Dividend Quality Index [1] Group 2 - Jinyang Co. announced a cash dividend of 2.00 RMB per 10 shares (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [1] - Shihua Technology declared a cash dividend of 0.40 RMB per share (tax included), with a record date of December 4, 2025, and an ex-dividend date of December 5, 2025 [2] - Jindi Co. announced a cash dividend of 0.15 RMB per share (tax included), with a record date of December 4, 2025, and an ex-dividend date of December 5, 2025 [2] - Daosheng Tianhe declared a cash dividend of 0.15 RMB per share (tax included), with a record date of December 4, 2025, and an ex-dividend date of December 5, 2025 [2] - Meihao Medical announced a cash dividend of 0.80 RMB per 10 shares (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [3] - Guizhou Tire declared a cash dividend of 0.40 RMB per 10 shares (tax included), with a record date of December 4, 2025, and an ex-dividend date of December 5, 2025 [3] - Hangu Group announced a cash dividend of 3.60 RMB per 10 shares (tax included), with a record date of December 5, 2025, and an ex-dividend date of December 8, 2025 [3]

证 券 研 究 报 告 行业周报 关注吸入制剂在呼吸疾病领域的突破 医药行业周报 投资评级： 报告日期： 推荐 （ 维持 ） 2025年11月30日 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 在呼吸疾病领域，如IPF、COPD等，吸入制剂+新靶点组合正取得更多积极的治疗效果。2025年6月10日，Insmed公布其 治疗PAH(肺动脉高压）新药TPIP（曲前列环素棕榈醇吸入粉剂）的临床2b期顶线数据，安慰剂校正的PVR较基线降低35%， LS均值比0.65（p＜0.001）。其冻干粉制剂的设计，不仅实现了用药的方便性，只需每日一次，而且治疗效果也优于曲前 列环素的口服品种。7月9日，默沙东宣布收购一家专注于呼吸系统疾病的生物制药公司Verona Pharma，总交易价值约为 100亿美元。通过此次收购，默沙东将获得一款用于治疗慢性阻塞性肺病（COPD）的重磅新药Ohtuvayre（恩司芬群）， 这是一种针对磷酸二酯酶3和4（PDE3和PDE4）的首创选择性双重抑制剂。FDA于2024年6月批准Ohtuvayre用 ...

Core Insights - The year 2025 is viewed as a pivotal year for China's "brain-computer interface" (BCI) industry, with significant policy support and investment activity driving growth [2][5][7] Policy Support - The "14th Five-Year Plan" emphasizes BCI as one of the six key future industries, indicating strong governmental backing [7] - In July, multiple departments released implementation opinions to promote innovation and development in the BCI sector, establishing clear timelines for industry growth [5] - By 2027, breakthroughs in key technologies are expected, with the establishment of advanced technical, industrial, and standard systems [6] Market Performance - As of November, the BCI sector in China has seen 28 financing rounds totaling over 5 billion yuan [2] - The BCI concept index in the A-share market has surged by 52.13% over the past year, significantly outperforming the CSI 300 index, which rose by 15.04% [2] - Notable A-share companies in the BCI space, such as Innovation Medical and Hanwei Technology, have seen stock price increases of 170% and 139.48%, respectively [2] Industry Development - Shanghai has proactively laid out plans for BCI development, aiming for high-quality brain control and clinical applications by 2027 [8] - The BCI industry in China is rapidly advancing, with over 800 core enterprises identified, primarily located in China and the U.S. [9] - China is positioned to potentially lead in the BCI sector, with significant clinical advancements, including the first invasive clinical trial conducted in June [9][10] Financial Performance - In the A-share market, 24 companies related to BCI reported an average revenue of 3.428 billion yuan and an average net profit of 431 million yuan for the first three quarters [11] - Despite high gross profit margins, with 18 companies exceeding 30% and 9 over 60%, some companies are facing negative growth in revenue and net profit [12] Company Initiatives - Companies like Lepu Medical and Meihua Medical are actively pursuing commercialization of BCI products, with Lepu focusing on deep brain stimulation devices and Meihua collaborating with leading cochlear implant firms [13][14] - Aipeng Medical has received regulatory approval for its EEG collection products, which are part of a new ADHD treatment system, and is working with hospitals to implement these solutions [14]

Core Viewpoint - The article highlights the rapid development and investment opportunities in China's brain-computer interface (BCI) industry, which is expected to become a key focus area by 2025, supported by strong government policies and significant capital market activity [1][6][9]. Policy Support - The "14th Five-Year Plan" emphasizes BCI as one of the six key future industries, with increasing policy support and strategic importance [6][7]. - In July, multiple government departments released implementation opinions to promote BCI innovation, setting clear development milestones for the industry [6]. - By 2027, breakthroughs in key technologies are expected, with the establishment of advanced technical, industrial, and standard systems [6]. - Shanghai has initiated a plan to cultivate the BCI industry from 2025 to 2030, aiming for clinical applications of semi-invasive BCI products by 2027 [7][8]. Market Performance - The BCI concept index in the A-share market has seen a significant increase of 52.13% over the past year, outperforming the Shanghai and Shenzhen 300 index, which rose by 15.04% [1]. - Notable BCI-related stocks include Innovation Medical and Hanwei Technology, with year-to-date increases of 170% and 139.48%, respectively [2][1]. Industry Landscape - China is positioned to lead in the BCI sector, with over 800 core enterprises in the industry, primarily located in China and the U.S. [10]. - The first invasive clinical trial in China was successfully conducted in June, marking a significant milestone in the country's BCI technology development [10][11]. - The "North Brain No. 1" GCP multi-center clinical trial was launched in October, representing a new phase in large-scale clinical validation of BCI systems [11]. Financial Performance - In the A-share market, 24 companies related to BCI reported an average revenue of 3.428 billion yuan and an average net profit of 431 million yuan for the first three quarters [13]. - 18 companies have a gross margin exceeding 30%, indicating strong profitability, although many companies are facing challenges in revenue and profit growth [13]. - Companies like Lepu Medical and Aipeng Medical are actively working on commercialization and product development in the BCI space, with recent regulatory approvals and strategic partnerships [14].

2025年被产业界视为中国"脑机接口"的元年。 首先是政策端，"十五五"规划建议明确将"脑机接口"作为重点布局的六大未来产业之一；其次，资本市 场投融资表现火热，据动脉橙数据库不完全统计，截至今年11月，我国脑机接口领域今年已完成28起融 资，融资总额超过50亿元。 在A股市场，"脑机接口"也成为投资风口。以万得脑机接口概念指数（8841700.WI）为例，近一年涨幅 高达52.13%，同期沪深300上涨15.04%。 喊了多年的脑机接口，产业到底发展如何？离商业化还有多远？A股业内公司业务进展情况又是怎样？ 政策持续加码 从"脑机接口"政策推动来看，今年以来力度不断加大，并且上升至国家战略。 7月，七部门发布关于推动脑机接口产业创新发展的实施意见，提出了明确的产业发展时间节点。 到2027年，脑机接口关键技术取得突破，初步建立先进的技术体系、产业体系和标准体系。产业规模不 断壮大，打造2至3个产业发展集聚区，开拓一批新场景、新模式、新业态。 到2030年，脑机接口产业创新能力显著提升，形成安全可靠的产业体系，培育2至3家有全球影响力的领 军企业和一批专精特新中小企业，构建具有国际竞争力的产业生态，综合实力迈 ...

最新公告列表 《2025年前三季度权益分派实施公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月28日收盘，美好医疗（301363）报收于21.23元，较前一交易日上涨0.66%，最新总市值 为120.77亿元。该股当日开盘21.09元，最高21.35元，最低21.01元，成交额达6742.93万元，换手率为 0.85%。 近日，美好医疗发布2025年前三季度权益分派实施公告。公告显示，公司2025年前三季度权益分派方案 已获通过，以总股本568,871,180股剔除回购股份1,132,048股后的567,739,132股为基数，向全体股东每10 股派发现金红利0.80元（含税），合计派发45,419,130.56元。本次不送红股，不进行资本公积转增股 本。股权登记日为2025年12月5日，除权除息日为2025年12月8日。现金红利由中国结算深圳分公司代 派，部分股东由公司自行派发。 ...

证券日报网讯 11月28日晚间，美好医疗发布公告称，本公司2025年前三季度权益分派方案为：以公司 现有总股本568，871，180股剔除回购专用证券账户中1，132，048股后的567，739，132股为基数，向 全体股东每10股派0.800000元人民币现金（含税）。股权登记日为2025年12月5日，除权除息日为2025 年12月8日。 （文章来源：证券日报） ...

1 证券代码：301363 证券简称：美好医疗 公告编号：2025-074 深圳市美好创亿医疗科技股份有限公司 2025年前三季度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、截至本公告披露日，深圳市美好创亿医疗科技股份有限公司（以下简称 "公司"或"本公司"）回购专用证券账户持有公司股份 1,132,048 股。根据《上 市公司股份回购规则》及《深圳证券交易所上市公司自律监管指引第 9 号——回 购股份》等相关规定，该部分已回购的股份不享有参与本次利润分配的权利。因 此，公司本次权益分派以现有总股本 568,871,180 股剔除回购专用证券账户持有 的 1,132,048 股后的 567,739,132 股为基数，向全体股东每 10 股派发现金红利人 民币 0.80 元（含税），合计派发现金红利人民币 45,419,130.56 元（含税）。本 次不送红股，不进行资本公积转增股本。 2、本次权益分派实施后，按公司总股本（含回购股份）折算的每 10 股现金 分红（含税）=本次实际现金分红总额÷公司总股本（含回购股份）×10 ...

Core Viewpoint - The stock of Meihao Medical (301363) has shown fluctuations in trading volume and capital flow, with a slight increase in share price on November 27, 2025, despite net outflows from major and retail investors [1][2]. Financial Performance - For the first three quarters of 2025, Meihao Medical reported a main revenue of 1.194 billion yuan, a year-on-year increase of 3.28%, while the net profit attributable to shareholders was 208 million yuan, a decrease of 19.25% [3]. - In Q3 2025, the company achieved a single-quarter main revenue of 462 million yuan, up 2.56% year-on-year, and a net profit of 93.90 million yuan, an increase of 5.89% year-on-year [3]. - The company's gross profit margin stands at 39.34%, with a net profit margin of 17.43% [3]. Market Position - Meihao Medical's total market capitalization is 11.997 billion yuan, which is higher than the industry average of 11.026 billion yuan, ranking 25th out of 124 in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 43.22, which is lower than the industry average of 56.75, ranking 48th out of 124 [3]. - The return on equity (ROE) is 5.79%, significantly higher than the industry average of 0.15%, ranking 43rd out of 124 [3]. Investor Sentiment - Over the past 90 days, 14 institutions have rated the stock, with 12 buy ratings and 2 hold ratings, indicating positive sentiment among analysts [4]. - The average target price set by institutions for the stock is 25.2 yuan [4].

Industry Overview - The year 2025 is regarded as the "year of brain-computer interfaces" in China, with significant policy support and investment activity in the sector [1][2] - The "14th Five-Year Plan" has identified brain-computer interfaces as one of the six key future industries for strategic development [4] Policy Support - In July, multiple government departments released implementation opinions to promote innovation and development in the brain-computer interface industry, setting clear development timelines [3] - By 2027, breakthroughs in key technologies are expected, with the establishment of advanced technical, industrial, and standard systems [3] - By 2030, the industry aims to enhance innovation capabilities and cultivate globally influential leading enterprises [3] Investment Landscape - As of November, the brain-computer interface sector in China has completed 28 financing rounds, totaling over 5 billion yuan [1] - The brain-computer interface concept index (8841700.WI) has seen a 50.74% increase over the past year, outperforming the Shanghai and Shenzhen 300 index, which rose by 17.64% [1] Company Developments - A total of 24 companies in the A-share market are involved in the brain-computer interface sector, with average revenues of 3.428 billion yuan and average net profits of 431 million yuan in the first three quarters [8] - However, there is significant variance in performance, with 8 companies reporting losses and 11 companies with net profits below 100 million yuan [10] - Companies like Mindray Medical and 37 Interactive Entertainment reported net profits exceeding 1 billion yuan [10] Clinical Advancements - In June, China became the second country globally to conduct invasive clinical trials for brain-computer interfaces, marking a significant milestone in the field [6] - The "North Brain No. 1" GCP multi-center clinical trial was launched in October, representing the first high-throughput, wireless, fully implanted semi-invasive brain-computer system [7] Market Potential - The brain-computer interface industry is expected to grow rapidly, with companies like Lepu Medical and Meihua Medical actively pursuing commercialization of their products [10][11] - Lepu Medical is working on deep brain stimulation devices, while Meihua Medical collaborates with global cochlear implant leaders to develop invasive brain-computer interface products [10][11] - Aipeng Medical has received approval for its EEG collection products and is focusing on ADHD treatment solutions, with new pricing policies being introduced for brain-computer interface services [11]